Localization Studies of Rare Missense Mutations in Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Facilitate Interpretation of Genotype-Phenotype Relationships

被引:39
|
作者
Krasnov, Kristina V. [1 ]
Tzetis, Maria [2 ]
Cheng, Jie [3 ]
Guggino, William B. [3 ]
Cutting, Garry R. [1 ]
机构
[1] Johns Hopkins Univ, Johns Hopkins Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA
[2] Univ Athens, Dept Genet, Athens, Greece
[3] Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA
基金
美国国家卫生研究院;
关键词
cystic fibrosis; CF; CFTR; polarized cells; complex allele; recombinase-mediated integration;
D O I
10.1002/humu.20866
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
We have been investigating the functional consequences of rare disease-associated amino acid substitutions in the cystic fibrosis transmembrane conductance regulator (CFTR). Mutations of the arginine residue at codon 1070 have been associated with different disease consequences; R1070P and R1070Q with "severe" pancreatic insufficient cystic fibrosis (CF) and R1070W with "mild" pancreatic sufficient CF or congenital bilateral absence of the vas deferens. Intriguingly, CFTR bearing each of these mutations is functional when expressed in nonpolarized cells. To determine whether R1070 mutations cause disease by affecting CFTR localization, we created polarized Madin Darby canine kidney (MDCK) cell lines that express either)wild-type or mutant CFTR from the same genomic integration site. Confocal microscopy and biotinylation studies revealed that R1070P was not inserted into the apical membrane, R1070W was inserted at levels reduced from wild,type while R1070Q was present in the apical membrane at levels comparable to wild-type. The abnormal localization of CFTR bearing R1070P and R1070W was consistent with deleterious consequences in patients; however, the profile of CFTR R1070Q was inconsistent with a "severe" phenotype. Reanalysis of 16 patients with the R1070Q mutation revealed that 11 carried an in cis nonsense mutation, S466X. All 11 patients carrying the complex allele R1070Q-S466X had severe disease, while 4 out of 5 patients with R1070Q had "mild" disease, thereby reconciling the apparent discrepancy between the localization studies of R1070Q and the phenotype of patients bearing this mutation. Our results emphasize that localization studies in relevant model systems can greatly assist the interpretation of the disease,causing potential of rare missense mutations. Hum Mutat 29 (11), 1364-1372, 2008. (C) 2008 Wiley-Liss, Inc.
引用
收藏
页码:1364 / 1372
页数:9
相关论文
共 50 条
  • [31] Early life of cystic fibrosis transmembrane conductance regulator (CFTR) in the cell
    Riordan, JR
    Gentzsch, M
    Hammerle, M
    Chen, JH
    Mengos, A
    Jensen, T
    Chang, XB
    KIDNEY INTERNATIONAL, 2001, 60 (02) : 401 - 401
  • [32] Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone
    Shead, Elizabeth F.
    Haworth, Charles S.
    Condliffe, Alison M.
    McKeon, Damian J.
    Scott, Mike A.
    Compston, Juliet E.
    THORAX, 2007, 62 (07) : 650 - 651
  • [33] Identification of cystic fibrosis transmembrane conductance regulator gene (CFTR) variants
    Almaghamsi, Talal
    Attiyah, Wejdan Ba
    Bahasan, Mona
    Alotaibi, Badi A.
    Alahmadi, Shahad F.
    Hanbazazh, Mehenaz
    Zakariyah, Abeer
    Saleem, Rimah A.
    AlAnezi, Munaifah K.
    Hawsawi, Yousef
    SAUDI MEDICAL JOURNAL, 2023, 44 (10) : 987 - 994
  • [34] Identification of cystic fibrosis transmembrane regulator (CFTR) mutations in Chilean patients with cystic fibrosis
    Repetto, G
    Poggi, H
    Harris, P
    Navarro, H
    Sánchez, I
    Guiraldes, E
    Pérez, MA
    Boza, ML
    Hunter, B
    Wevar, ME
    Mediavilla, M
    Foradori, A
    REVISTA MEDICA DE CHILE, 2001, 129 (08) : 841 - 847
  • [35] Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitylation as a Novel Pharmaceutical Target for Cystic Fibrosis
    Fukuda, Ryosuke
    Okiyoneda, Tsukasa
    PHARMACEUTICALS, 2020, 13 (04)
  • [36] EPIGENETIC REGULATION OF AUTOPHAGY AND CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) FUNCTION IN CYSTIC FIBROSIS
    Amer, A.
    Tazi, M.
    Caution, K.
    PEDIATRIC PULMONOLOGY, 2015, 50 : 285 - 285
  • [37] Clinical implications of cystic fibrosis transmembrane conductance regulator mutations
    Mickle, JE
    Cutting, GR
    CLINICS IN CHEST MEDICINE, 1998, 19 (03) : 443 - +
  • [38] Association of cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and primary sclerosing cholangitis (PSC)
    Balan, V
    Yurk, C
    Wang, NL
    Rakela, J
    Charlton, M
    Cutting, G
    GASTROENTEROLOGY, 2003, 124 (04) : A712 - A712
  • [39] Prevalence of meconium ileus marks the severity of mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene
    Dupuis, Annie
    Keenan, Katherine
    Ooi, Chee Y.
    Dorfman, Ruslan
    Sontag, Marci K.
    Naehrlich, Lutz
    Castellani, Carlo
    Strug, Lisa J.
    Rommens, Johanna M.
    Gonska, Tanja
    GENETICS IN MEDICINE, 2016, 18 (04) : 333 - 340
  • [40] Studies of conformational changes in cystic fibrosis transmembrane conductance regulator (CFTR) associated with channel activation
    Ugwu, F.
    Ramjeesingh, M.
    Woolley, G. A.
    Bear, C. E.
    BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE, 2006, 84 (06): : 1078 - 1078